GIM-0621
Undisclosed
Preclinical/DiscoveryActive
Key Facts
About Georgiamune
Georgiamune is a private, preclinical-stage biotech leveraging a proprietary target discovery platform to develop novel immunomodulators. The company's strategy centers on rebalancing the immune system with first-in-class assets, including a dual-functioning antibody for cancer and small molecules that either inhibit or activate regulatory T cells (Tregs) for cancer and autoimmune diseases, respectively. Headquartered in Gaithersburg, MD, Georgiamune is building a portfolio aimed at large indications with high unmet need. It operates as a pre-revenue company with a team experienced in biopharma R&D.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |